BR112014027653A2 - formulações para a liberação dos ingredientes ativos - Google Patents

formulações para a liberação dos ingredientes ativos

Info

Publication number
BR112014027653A2
BR112014027653A2 BR112014027653A BR112014027653A BR112014027653A2 BR 112014027653 A2 BR112014027653 A2 BR 112014027653A2 BR 112014027653 A BR112014027653 A BR 112014027653A BR 112014027653 A BR112014027653 A BR 112014027653A BR 112014027653 A2 BR112014027653 A2 BR 112014027653A2
Authority
BR
Brazil
Prior art keywords
formulations
release
active ingredients
methods
active ingredient
Prior art date
Application number
BR112014027653A
Other languages
English (en)
Inventor
C Yeomans David
Miljanich George
Mamet Julien
Orr Rick
Harris Scott
Yaksh Tony
K Schmidt William
Original Assignee
Adynxx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adynxx Inc filed Critical Adynxx Inc
Publication of BR112014027653A2 publication Critical patent/BR112014027653A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

abstract this invention relates generally to in vivo delivery of active ingredient formulations. more particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same. --------------------------------------------------------------------------------------------------------- tradução do resumo resumo patente de invenção: "formulações para a liberação dos ingredientes ativos". esta invenção refere-se de uma forma geral à liberação in vivo das formulações de ingrediente ativo. mais particularmente, esta invenção refere-se às formulações de ingredientes ativos que ainda compreendem um agente, métodos de preparação de tais formulações, e métodos da sua utilização.
BR112014027653A 2012-05-10 2013-05-09 formulações para a liberação dos ingredientes ativos BR112014027653A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645475P 2012-05-10 2012-05-10
PCT/US2013/040426 WO2013170086A2 (en) 2012-05-10 2013-05-09 Formulations for the delivery of active ingredients

Publications (1)

Publication Number Publication Date
BR112014027653A2 true BR112014027653A2 (pt) 2017-08-08

Family

ID=49551465

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014027653A BR112014027653A2 (pt) 2012-05-10 2013-05-09 formulações para a liberação dos ingredientes ativos

Country Status (12)

Country Link
US (3) US9700624B2 (pt)
EP (2) EP2846839B1 (pt)
JP (2) JP6251247B2 (pt)
CN (1) CN104487096B (pt)
AU (1) AU2013259402B2 (pt)
BR (1) BR112014027653A2 (pt)
CA (1) CA2872901A1 (pt)
ES (1) ES2724851T3 (pt)
HK (1) HK1208188A1 (pt)
PT (1) PT2846839T (pt)
RU (1) RU2668136C2 (pt)
WO (1) WO2013170086A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2818550B1 (en) 2007-05-11 2016-12-28 Adynxx, Inc. Gene expression and pain
BR112014027653A2 (pt) 2012-05-10 2017-08-08 Adynxx Inc formulações para a liberação dos ingredientes ativos
WO2016025829A1 (en) * 2014-08-15 2016-02-18 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
RU2723032C2 (ru) * 2014-12-29 2020-06-08 Бонак Корпорейшн Композиция, стабильно содержащая молекулу нуклеиновой кислоты
US20200017853A1 (en) * 2016-02-29 2020-01-16 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
KR100225087B1 (ko) 1990-03-23 1999-10-15 한스 발터라벤 피타아제의 식물내 발현
US5272056A (en) 1991-01-03 1993-12-21 The Research Foundation Of State University Of New York Modification of DNA and oligonucleotides using metal complexes of polyaza ligands
US5683985A (en) 1991-04-18 1997-11-04 The Salk Institute For Biological Studies Oligonucleotide decoys and methods relating thereto
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
AU7518194A (en) 1993-07-29 1995-02-28 Regents Of The University Of California, The Polynucleotide decoys that ihnibit mhc-ii expression and uses thereof
PT732929E (pt) 1993-10-29 2008-08-26 Brigham & Womens Hospital Utilização terapêutica de ''engodos'' de elementos cis in vivo
AU3881095A (en) * 1994-11-17 1996-06-17 Taiho Pharmaceutical Co., Ltd. Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
AU5369396A (en) 1995-03-23 1996-10-08 Research Foundation Of The State University Of New York, The Rest protein and dna
DE69533264T2 (de) 1995-05-11 2004-11-25 Applied Research Systems Ars Holding N.V. Inhibitoren der il-6 aktivitaet
PT824918E (pt) 1995-05-12 2007-06-22 Anges Mg Inc Tratamento e prevenção para doenças causadas pelo nf-kb
GB9515356D0 (en) 1995-07-26 1995-09-20 Medical Res Council Improvements in or relating to delivery of nucleic acid
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
ATE383172T1 (de) 1996-05-20 2008-01-15 Us Gov Health & Human Serv Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden
US6022863A (en) 1996-05-21 2000-02-08 Yale University Regulation of gene expression
JP4215219B2 (ja) 1997-07-04 2009-01-28 アンジェスＭｇ株式会社 脳保護剤
JP3667047B2 (ja) 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
US6060310A (en) 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
AU1656299A (en) 1997-12-16 1999-07-05 University Of Saskatchewan Conductive metal-containing nucleic acids
IL139936A0 (en) 1998-06-02 2002-02-10 Glaxo Group Ltd Gene therapy method
US6818626B1 (en) 1998-07-17 2004-11-16 Mirus Corporation Chelating systems for use in the delivery of compounds to cells
US6423493B1 (en) 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
US6008048A (en) 1998-12-04 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of EGR-1 expression
US7160869B2 (en) 1998-12-16 2007-01-09 University Of Saskatchewan Biologically active metal-containing nucleic acids
AU761136B2 (en) 1998-12-23 2003-05-29 Genentech Inc. Transfectacons comprising calcium phosphate and a nucleic acid
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6333408B1 (en) 1999-03-08 2001-12-25 Kureha Chemical Industry Co., Ltd. Oligonucleotides inhibitors of PAI-1 MRNA
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US6599741B1 (en) 1999-09-14 2003-07-29 Avontec Gmbh Modulating transcription of genes in vascular cells
US6927027B2 (en) 1999-12-21 2005-08-09 Ingeneus Corporation Nucleic acid multiplex formation
US6969704B1 (en) 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
DE10049549A1 (de) 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
WO2002030355A2 (en) * 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
EP1344536A4 (en) * 2000-11-24 2005-01-19 Chugai Pharmaceutical Co Ltd METHOD FOR REGULATING THE ACTIVITY OF EXPRESSION OF A GENETIC PRODUCT TRANSFERRED INTO A LIVING ORGANISM
WO2002066071A2 (en) 2001-01-03 2002-08-29 Thomas Jefferson University Treatment of tissue fibrosis by blocking the sp1 transcription factor
WO2002057480A2 (en) 2001-01-22 2002-07-25 Genta Incorporated Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers
TWI308492B (pt) 2001-02-20 2009-04-11 Anges Mg Inc
WO2002070668A2 (en) 2001-03-06 2002-09-12 Sierra Sciences, Inc. Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
US20030166555A1 (en) 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
EP1298141A1 (en) 2001-09-27 2003-04-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2
DE10148828B4 (de) 2001-10-04 2005-05-19 Avontec Gmbh Modulation der Expression STAT-1-abhängiger Gene
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
CA2474645C (en) 2002-02-01 2011-08-09 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
CN1665929A (zh) 2002-04-26 2005-09-07 安琪士多摩奇株式会社 含有转录dna结合位点的环状哑铃状诱饵寡脱氧核苷酸(cdodn)
DE10242319A1 (de) 2002-09-12 2004-03-25 Avontec Gmbh Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
AU2003263523A1 (en) * 2002-10-09 2004-05-04 Pfizer Products Inc. Stabilized naked dna compositions
KR20110079741A (ko) * 2002-12-09 2011-07-07 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
DE10257421A1 (de) 2002-12-09 2004-07-08 Grünenthal GmbH Regulatorische Elemente im 5'-Bereich des VR1-Gens
WO2005004702A2 (en) * 2003-06-30 2005-01-20 Massachusetts Institute Of Technology Egr genes as targets for the diagnosis and treatment of schizophrenia
WO2005027830A2 (en) 2003-09-12 2005-03-31 Virginia Commonwealth University Chimeric transcription factor decoy oligonucleotides
JP2005336081A (ja) 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
US7482158B2 (en) 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
US20060293264A1 (en) 2004-07-22 2006-12-28 Grandis Jennifer R STAT3 decoy oligonucleotides and uses therefor
EP1799271A4 (en) 2004-09-21 2010-05-05 Anesiva Inc ADMINISTRATION OF POLYNUCLEOTIDES
JP4991547B2 (ja) 2004-09-28 2012-08-01 クアーク・ファーマスーティカルス、インコーポレイテッド 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法
EP1803811B1 (en) 2004-10-22 2011-05-11 AnGes MG, Inc. Chimeric (double) decoy
US7585848B2 (en) 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US8268572B2 (en) 2005-03-04 2012-09-18 Dana-Farber Cancer Institute, Inc. Methods to identify inhibitors of Runx1-mediated expression of nociceptive receptors and ion channels
EP1877556B1 (en) 2005-03-25 2011-09-14 Medtronic, Inc. Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain
EP3827841B1 (en) 2006-10-09 2024-04-03 Neurofluidics, Inc. Cerebrospinal fluid purification system
WO2008131129A2 (en) 2007-04-17 2008-10-30 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
AU2014201462B2 (en) 2007-05-11 2016-09-29 Adynxx, Inc. Gene expression and pain
EP2818550B1 (en) 2007-05-11 2016-12-28 Adynxx, Inc. Gene expression and pain
WO2011029092A1 (en) 2009-09-04 2011-03-10 University Of Miami Klf family members regulate intrinsic axon regeneration ability
WO2012021985A1 (en) * 2010-08-20 2012-02-23 Replicor Inc. Oligonucleotide chelate complexes
US20140275211A1 (en) 2011-06-21 2014-09-18 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
BR112014001335A2 (pt) 2011-07-20 2017-02-21 Hospira Inc método para tratar dor pós-operatória em um mamífero e método para tratar dor em um mamífero
BR112014027653A2 (pt) 2012-05-10 2017-08-08 Adynxx Inc formulações para a liberação dos ingredientes ativos
BR112014028654A2 (pt) 2012-05-18 2017-10-10 Replicor Inc composições de complexo de quelato de oligonucleotídeo-polipeptídeo e métodos
WO2016025829A1 (en) 2014-08-15 2016-02-18 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
US20200017853A1 (en) 2016-02-29 2020-01-16 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression

Also Published As

Publication number Publication date
AU2013259402A1 (en) 2014-11-27
EP2846839A2 (en) 2015-03-18
US9700624B2 (en) 2017-07-11
US20180015165A1 (en) 2018-01-18
US20150111956A1 (en) 2015-04-23
WO2013170086A3 (en) 2014-03-06
EP2846839B1 (en) 2019-02-20
JP6251247B2 (ja) 2017-12-20
CN104487096A (zh) 2015-04-01
RU2668136C2 (ru) 2018-09-26
EP2846839A4 (en) 2016-01-06
RU2014149700A (ru) 2016-07-10
JP2015517501A (ja) 2015-06-22
EP3511022A1 (en) 2019-07-17
CN104487096B (zh) 2020-09-15
JP6442027B2 (ja) 2018-12-19
ES2724851T3 (es) 2019-09-16
JP2018058866A (ja) 2018-04-12
US20190374644A1 (en) 2019-12-12
PT2846839T (pt) 2019-05-29
CA2872901A1 (en) 2013-11-14
WO2013170086A2 (en) 2013-11-14
HK1208188A1 (en) 2016-02-26
AU2013259402B2 (en) 2017-12-21
US10434178B2 (en) 2019-10-08

Similar Documents

Publication Publication Date Title
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
CY1123334T1 (el) Σκευασματα φιναστεριδης για αποδεσμευση φαρμακου στα μαλλια και στο τριχωτο της κεφαλης
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
BR112018003877A2 (pt) “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica”
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CL2012003573A1 (es) Combinaciones que comprenden un derivado de antranilamida y otro principio activo con propiedades insecticidas y acaricidas; composiciones agroquimicas que contienen; uso de dicha combinacion; procedimiento para combatir parasitos animales; y procedimiento para la preparacion de dicha composicion agroquimica.
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
BR112013017750A8 (pt) nanocápsulas com revestimento polimérico
BR112014027653A2 (pt) formulações para a liberação dos ingredientes ativos
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
NZ702967A (en) Diclofenac formulations
BR112015011430A2 (pt) composição para liberação imediata e prolongada
MX364800B (es) Tilmicosina de accion prolongada mejorada y el uso de la misma en el tratamiento del complejo respiratorio bovino (crb) y en el periodo de la vaca seca.
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
BR112017009510A2 (pt) composições compreendendo ciclosporina
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112017028468A2 (pt) formulação sólida oral, e método para preparar uma formulação sólida oral
MX2016001422A (es) Composicion farmaceutica de fingolimod.
BR112018010066A8 (pt) Agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo
CR20110226A (es) Composición para tratar enfermedad
CL2009002204A1 (es) Composicion intravenosa biocompatible que comprende un factor de coagulacion incluido en microparticulas de acido alginico o sales del mismo.
BR112018007399A2 (pt) composição, método de tratamento, kit de partes e forma de dosagem

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL